Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
NORQUEST FE is an oral contraceptive combining ethinyl estradiol and norethindrone (progestin) with ferrous fumarate supplementation in a 28-day tablet formulation. It prevents pregnancy through hormonal suppression of ovulation and is indicated for contraception in women of reproductive age. The ferrous fumarate component addresses iron loss from menstrual bleeding, providing dual contraceptive and nutritional benefit.
Product approaches loss of exclusivity with moderate competitive pressure (30/100), signaling declining team investment and potential portfolio consolidation.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
NORQUEST FE offers limited career growth due to its approaching LOE and mature market position; roles focus on generic defense, cost optimization, and portfolio management rather than innovation or expansion. Professionals seeking dynamic product development should consider earlier-stage assets within Pfizer's contraceptive and women's health portfolio.
Worked on NORQUEST FE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.